Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIGA Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (19)	4/24/2006 2:14:43 PM
From: caly	Read Replies (1) \| Respond to of 160

MedImmune is investing in a PharmAthene competitor... biz.yahoo.com bizjournals.com MedImmune to invest in N.J. biotech Monday April 24, 1:05 pm ET The venture capital subsidiary of MedImmune will make an equity investment in Elusys Therapeutics as part of a license and collaboration agreement. Gaithersburg-based MedImmune (NASDAQ:MEDI - News) did not say how much its MedImmune Ventures subsidiary would invest in Pine Brook, N.J.-based Elusys, a privately held developer of anti-infective drugs. MedImmune and Elusys will also develop and attempt to commercialize new drugs targeting infectious diseases. Elusys will receive an upfront payment, milestones and royalties on any future marketed products. The companies will jointly conduct preclinical work. MedImmune will be responsible for clinical development and worldwide commercialization of any products that result from the partnership. Elusys' lead product, Anthim, is in Phase I clinical studies. Anthim is a monoclonal antibody being developed for pre- and post-exposure to anthrax infection. Elusys is hoping for a large government contract, under Project BioShield, to supply the federal government with Anthim as public health officials try to stockpile medicines to defend against biological terrorist threats. Elusys is competing for a government contract with, among others, Rockville-based Human Genome Sciences (NASDAQ:HGSI - News) and Annapolis-based PharmAthene. Published April 24, 2006 by the Washington Business Journal